下载掌阅APP，畅读海量书库
立即打开
［1］Na R，Ye D，Qi J，et al. Prostate health index significantly reduced unnecessary prostate biopsies in patients with PSA 2-10ng/mL and PSA＞10ng/mL：Results from a Multicenter Study in China［J］. The Prostate，2017，77（11）：1221-1229.
［2］MARTIN，RICHARD M，DONOVAN，et al. Effect of a low-intensity psa-based screening intervention on prostate cancer mortality the CAP randomized clinical trial［J］. JAMA，2018，319（9）：883-895.
［3］HUANG D，RUAN X，WU Y，et al. Genetic polymorphisms at 19q13.33 are associated with ［-2］proPSA（p2PSA）levels and provide additional predictive value to prostate health index for prostate cancer［J］.Prostate，2021，81（13）：971-982.
［4］DE LUCA S，PASSERA R，CATTANEO G，et al. High prostate cancer gene 3（PCA3）scores are associated with elevated prostate imaging reporting and data system（PI-RADS）grade and biopsy Gleason score，at magnetic resonance imaging/ultrasonography fusion software-based targeted prostate biopsy after a previous negative standard biopsy［J］. BJU Int，2016，118（5）：723-730.
［5］丘佳明，宛传丹，QIU，等. 前列腺癌中 TMPRSS2 - ERG 融合基因作用机制的研究进展［J］. 临床与病理杂志，2017，37（11）：6.
［6］董隽，肖立，孙忠全，等. 前列腺癌E26转录因子家族基因融合发生率及其与临床病理指标相关性研究［J］. 中华泌尿外科杂志，2014，35（3）：195-199.
［7］TOMLINS，SCOTT A，DAY，et al. Urine TMPRSS2 ： ERG plus PCA3 for individualized prostate cancer risk assessment［J］. Eur Urol，2016，70（1）：45-53.
［8］VAN NESTE，LEANDER，HENDRIKS，et al. Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score［J］. Eur Urol，2016，70（5）：740-748.
［9］DIJKSTRA S，BIRKER I L，SMIT F P，et al. Prostate cancer biomarker profiles in urinary sediments and exosomes［J］. J Urol，2014，191（4）：1132-1138.
［10］WOO J，SANTASUSAGNA S，BANKS J，et al. Urine extracellular vesicle gata2 mrna discriminates biopsy result in men with suspicion of prostate cancer［J］. J Urol，2020，204（4）：691-700.
［11］MCKIERNAN J，DONOVAN M J，O’NEILL V，et al. A novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy［J］. JAMA Oncol，2016，2（7）：882-889.
［12］JAMES MCKIERNAN，MICHAEL J. DONOVAN，ERIC MARGOLIS，et al. A prospective adaptive utility trial to validate performance of a novel urine exosome gene expression assay to predict high-grade prostate cancer in patients with prostate-specific antigen 2-10ng/ml at initial biopsy［J］. Eur Urol，2018，74（6）：731-738.
［13］WANG，WEI-LIN WINNIE，SOROKIN，et al. Expression of small noncoding rnas in urinary exosomes classifies prostate cancer into indolent and aggressive disease［J］. J Urol，2020，204（3）：466-474.
［14］DE LA CALLE，CLAIRE，PATIL，et al. Multicenter evaluation of the prostate health index to detect aggressive prostate cancer in biopsy naive men［J］. J Urol，2015，194（1）：65-72.
［15］FOSSATI，NICOLA，BUFFI，et al. Preoperative prostate-specific antigen isoform p2psa and its derivatives，%p2psa and prostate health index，predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer：results from a multicentric European prospective study［J］. Eur Urol，2015，68（1）：132-138.
［16］FOLEY，ROBERT W，GORMAN，et al. Improving multivariable prostate cancer risk assessment using the Prostate Health Index［J］. BJU Int，2016，117（3）：409-417.
［17］张景良，秦卫军. 68 Ga-前列腺特异性膜抗原PET/CT在前列腺癌诊断中的研究进展［J］. 中华泌尿外科杂志，2018，39（10）：797-800.
［18］SJOBERG，DANIEL D，VICKERS，et al. Twenty-year risk of prostate cancer death by midlife prostatespecific antigen and a panel of four kallikrein markers in a large population-based cohort of healthy men［J］.Eur Urol，2018，73（6）：941-948.